Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002725 · ClinicalTrials.gov registry record · Phase 2

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
35
Enrollment target

NCT00002725: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00002725 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00002725, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target

Study Summary

Phase II trial to study the effectiveness of bryostatin-1 in treating patients with recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Interventions

  • DRUG chemotherapy
  • DRUG bryostatin 1

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1996-08
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00002725 record still lists

NCT00002725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.

NCT00002725 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002725 about?

NCT00002725 is a clinical study titled "Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma". Phase II trial to study the effectiveness of bryostatin-1 in treating patients with recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

What is the current status of trial NCT00002725?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1996-08.

What interventions are being tested in trial NCT00002725?

The interventions under investigation include: chemotherapy (DRUG), bryostatin 1 (DRUG).

Who is sponsoring clinical trial NCT00002725?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00002725's enrollment target sits among peer trials

35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002725, the US trial registry maintained by the National Library of Medicine. NCT00002725 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.